UT-San Antonio, Health Science Center, Merck Pen Exclusive Deal to Develop Chlamydia Vaccine | GenomeWeb

The University of Texas at San Antonio and the University of Texas Health Science Center at San Antonio said this week that they have entered into an exclusive license and sponsored-research agreement with Merck to develop a vaccine for chlamydia.

According to the schools, the deal is noteworthy because it is the first revenue-producing license for any technology developed at UTSA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.